Quick Answer
60 DEGREES PHARMACEUTICALS, INC. reported Net Income of -$7.37 million for fiscal year 2025.
60 DEGREES PHARMACEUTICALS, INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$7.37M | +7.3% |
| 2024 | -$7.95M | -111.0% |
| 2023 | -$3.77M | +39.1% |
| 2022 | -$6.18M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.32M | -7.2% | -33.6% |
| June 30, 2025 | -$1.73M | +58.5% | +7.6% |
| March 31, 2025 | -$1.88M | -535.9% | +13.1% |
| September 30, 2024 | -$2.16M | -151.6% | +48.2% |
| June 30, 2024 | -$4.17M | -25.1% | -1069.3% |
| March 31, 2024 | $430.5K | +116.6% | -89.7% |
| September 30, 2023 | $4.18M | +389.0% | +225.4% |
| June 30, 2023 | -$3.34M | -55.4% | -28.3% |
- 60 DEGREES PHARMACEUTICALS, INC. showed an increase of +7.3% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, 60 DEGREES PHARMACEUTICALS, INC.’s net income has declined by 19.1% (from -$6.18 million to -$7.37 million).
- The most recent figure is from 60 DEGREES PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: